Description

L-DOPA-2,5,6-d3 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].–20°C, 3 years; 4°C, 2 years (Powder)-Applications-Neuroscience-Neuromodulation-Formula-C9H8D3NO4-Citation–References-[1]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.|[2]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7.|[3]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson’s Disease. Front Aging Neurosci. 2018 Aug 3;10:237.|[4]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5.|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.-CASNumber-53587-29-4-MolecularWeight-200.21-Compound Purity-99.95-SMILES-C([C@@H](C(O)=O)N)C1=C(C(O)=C(O)C(=C1[2H])[2H])[2H]-Research_Area-Neurological Disease-Solubility-H2O : 25 mg/mL (ultrasonic;warming;adjust pH to 1 with HCl;heat to 60°C)-Target-Dopamine Receptor;Endogenous Metabolite-Isoform-D3 Receptor-Pathway-GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling-MCE Product type-Isotope-Labeled Compounds